Following the resistance pattern of mycobacterium tuberculosis

Shurbeska, Boneva Biljana; Nikolovska, Jasmina; Mitrevski, Vladimir; Zejnel, Sead; Chamurovski, Nikola; Merdžanovski, Ersin; Savin, Ivanovska Biljana; Aleksovska, Gjuzelova Aleksanda; Jorganovikj, Stojkoska Aleksandra; Bikova, Gjurgjica; Sandevski, Aleksandar; Filipce, Milcho; Nanović, Zorica; Metodieva, Marija; Pilovska, Karolina; Tushevska, Mitkovska Monika

doi:10.5937/BatutPHCO24029S

Actions

Book of Abstracts - International congress Public health – achievements and challenges

how to cite this article
share this article

Permalink

Metrics

citations in Portal: 0
citations in CrossRef:0
citations in Google Scholar:[]
visits in previous 30 days:28
full-text downloads in 30 days:0

article: 2 from 89

back to result list

Book of Abstracts - International congress Public health – achievements and challenges

2024, Oral presentations, pp. 74-74

Following the resistance pattern of mycobacterium tuberculosis

Shurbeska Boneva Biljana^a, Nikolovska Jasmina^b, Mitrevski Vladimir^a, Zejnel Sead^a, Chamurovski Nikola^a, Merdžanovski Ersin^a, Savin Ivanovska Biljana^a, Aleksovska Gjuzelova Aleksanda^a, Jorganovikj Stojkoska Aleksandra^a, Bikova Gjurgjica^a, Sandevski Aleksandar^a, Filipce Milcho^a, Nanović Zorica^c, Metodieva Marija^a, Pilovska Karolina^a, Tushevska Mitkovska Monika^a

^aInstitute for lung diseases and tuberculosis, Skopje, North Macedonia
^bCenter for Public Health Bitola, Bitola, North Macedonia
^cInstitute for lung diseases and tuberculosis, Skopje, North Macedonia + Goce Delcev University, Štip, North Macedonia

Keywords: tuberculosis; resistance; MDR

Abstract

Background: Tuberculosis (TB) accounts for over 40% of all mortality cases from communicable diseases in Europe.Multidrug-resistant TB (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs. 30 countries worldwide are classified as high multi drug resistant (MDR) TB burden countries, nine are in the European Region. The emergence of combined resistance to rifampicin and isoniazid (MDR-TB) is a matter of global concern. Methods and Objectives: Over a period of 10 years we examined patient specimens for TB. Culture-positive samples were subjected to identification, and those cultures identified as M. tuberculosis (MTB) complex were subjected to drug susceptibility testing (DST). DST for first-line drugs was performed using proportional method on Lowenstein Jensen, and in recent years, rapid molecular techniques recommended by WHO (GeneXpert). DST for second line drugs was assessed using Geno Type MTBDRsl. Results: In the period 2012-2022 we tested 1554 TB strains, 1449 (93,24%) were found to be sensitive and 99 (6,37%) resistant to first-line drugs. 75 strains (4,83%) were monoresistant, 15 (0,96%) of which were resistant only to Rifampicin. Of the total 1423 strains, 22 (1,41%) were found to be MDR. Conclusions: Currently a low 1,41% of our isolates are MDR. It is necessary to strengthen our TB laboratory capacity for early detection of drug-resistant TB. This is best done by using rapid molecular diagnosis as an initial method for all cases with clinical suspicion of TB.